Viridian Therapeutics To Present VRDN-008 Phase 1 Data And Outline FcRn Portfolio Development Plans On Monday, November 9, 2026, At 8:00 a.m. ET
Benzinga Newsdesk 1 hour ago
BiotechGeneralNews
Viridian Therapeutics, Inc. (NASDAQ:VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for autoimmune and rare diseases, today announced it will
Viridian Therapeutics, Inc. (NASDAQ:VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for autoimmune and rare diseases, today announced it will host a conference call and webcast to present data from the VRDN-008 phase 1 clinical trial in healthy volunteers and development plans for its neonatal Fc receptor (FcRn) portfolio on Monday, November 9, 2026, at 8:00 a.m. ET.
Conference Call and Webcast Information
Viridian will host a conference call and webcast Monday, November 9, at 8:00 a.m. ET to present the VRDN-008 phase 1 data and discuss development plans for the FcRn portfolio. The dial-in number for the conference call is +1 833-461-5787 for domestic participants and +1 585-542-9983 for international participants. The conference ID is 798750309.
A live webcast of the conference call can be accessed under "Events & Presentations" on the Investors section of the Viridian website at viridiantherapeutics.com. Following the live webcast, an archived version of the call will also be available on the Viridian website.